| |
| Dissanayake
SK, Thompson
JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg
S. |
| |
Activation of tumor-specific CD4(+) T lymphocytes
by major histocompatibility complex class II tumor cell
vaccines: a novel cell-based immunotherapy. Cancer Res.
2004 64:1867-1874. [PubMed
listing][PDF]. |
| Ostrand-Rosenberg
S, Clements V, Dissanayake SK,
Gilbert M, Pulaski B, Qi L |
| |
Immunologic
targets for the gene therapy of cancer, in: Gene Therapy
of Cancer, 2nd edition (Lattime and Gerson, eds.),
Academic Press, pp. 127-142 2002. |
| Ostrand-Rosenberg
S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake
SK |
| |
Resistance
to metastatic disease in STAT6-deficient mice requires
hemopoietic and nonhemopoietic cells and is IFN-gamma
dependent. J Immunol. 2002 169:5796-804. [PubMed
listing] [PDF
file] |
|
|
